Savara to discontinue exploratory encore study evaluating molgradex for treatment of ntm lung infection

Savara to discontinue exploratory encore study evaluating molgradex for the treatment of ntm lung infection in people living with cystic fibrosis (cf).savara inc - encore study stopped enrolling in march 2020 due to limitations caused by covid-19.savara inc - decision to discontinue encore study was not based on safety concerns.savara inc - does not plan to conduct further development activities related to molgradex in ntm.
SVRA Ratings Summary
SVRA Quant Ranking